目的研究地尔硫主要活性代谢产物体内的药动学，评价代谢产物在地尔硫临床治疗中的作用。方法以8名健康志愿者为对象，采用了单剂量(90 mg) 和多剂量(90 mg,bid)的给药方案，于给药后不同时间取血，血中地尔硫(上)艹(下)卓、去乙酰基地尔硫(M1)和N去甲基地尔硫(Ma)的浓度采用高效液相法测定。结果药时曲线显示地尔硫(上)艹(下)卓经代谢,很快转化为去乙酰基地尔硫和N-去甲基地尔硫(上)艹(下)卓，多剂量显示明显的累积效应。药动学参数显示了地尔硫(上)艹(下)卓、去乙酰基地尔硫(上)艹(下)卓和去甲基地尔硫(上)艹(下)卓消除速率依次下降。地尔硫(上)艹(下)卓的曲线下面积，多剂量是单剂量的2倍，但两个代谢产物的仅为0.79和0.58倍；代谢产物与地尔硫(上)艹(下)卓的曲线下面积比值的变化，M1从单剂量的1.3降为多剂量的0.72，Ma从单剂量的1.04降为多剂量的0.32，表明多剂量时Ma的量明显减少。结论以上结果提示多剂量时存在着代谢酶的抑制作用，尤其是对地尔硫(上)艹(下)卓的代谢成Ma的途径的抑制作用较M1更明显，可能也是引起地尔硫(上)艹(下)卓的蓄积效应的原因之一。建议当临床长期使用地尔硫(上)艹(下)卓时，应适当地监测血药浓度。
Abstract
OBJECTIVE To study the pharmacokinetics of the main active metabolites of diltiazem(DTZ).To evaluate the role of the metabolites of diltiazem,deacetyldiltiazem (M1) and N-monodesmethyldiltiazem (Ma) in clinical treatment.METHODS Eight healthy volunteers were given diltiazem 90 mg by single and multiple oral dose and the blood samples were collected at different time after administration.The plasma concentrations of M1 and Ma were determined by HPLC. RESULTS Diltiazem was quickly metabolized into its metabolites,M1 and Ma.The levels of M1 were higher than that of Ma.The multiple dose administration showed significant accumulation effect.The pharmacokinetic parameters showed that the elimination rates of DTZ,M1 and Ma declined successively.The ratios of the areas under curve of DTZ ,M1 and Ma after multiple dose compared with that after single dose were 2,0.79 and 0.58 respectively.AUCM1/AUCDTZdropped from 1.3 of single dose to 0.72 of multiple dose.AUCMa/AUCDTZdropped from 1.04 of single dose to 0.32 of multiple dose.The data showed that the amount of Ma decreased evidently. CONCLUSION It indicated that the inhibition of metabolic enzyme，especially,the inhibitory effect on DTZ changed into Ma was more significant than that on DTZ changed into M1,which may cause accumulation effect after multiple dose.The plasma concentrations of diltiazem are suggested to be monitored when diltiazem is dosed for a long term.
关键词
药动学 /
代谢产物 /
地尔硫 /
去乙酰基地尔硫 /
N-去甲基地尔硫
{{custom_keyword}} /
Key words
pharmacokinetics /
metabolites /
diltiazem /
M1 /
Ma
{{custom_keyword}} /
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1]Weir M.Diltiazem:ten years of clinical experience in treatment of hypertension[J]. J Clin Pharmacol,1995,35:220.
[2]Homsy W,Lefebvre M,Caille G.Metabolism of diltiazem in hepatic and extrahepatic tissues of rabbits:in vitro studies[J]. Pharm Res,1995,12:609.
[3]Yabana H,Nagao T,Sato M.Cardiovascular effects of the metabolites of diltiazem in dogs[J]. J Cardiovasc Pharmacol,1985,7:152.
[4]Yeung PK,Prescott C，Haddad C, et al. Pharmacokinetics and metabolism of diltiazem in healthy males and females following a single oral dose[J]. Eur J Drug Metab Pharmacokinet,1993,18:199.
[5]Hoglund P,Nilsson LG.Pharmacokinetics of diltiazem and its metabolites after repeated multiple-dose treatments in healthy volunteers[J]. Ther Drug Monit,1989,11:543.
[6]杜云龙，楼雅卿.钙拮抗剂的临床药代动力学[J].中国临床药理学杂志,1989,5:118.
[7]Robbins-Weilert DK,Giesing DH,Weir SJ.Steady-state pharmacokinetics of high-dose diltiazem hydrochloride (Cardizem CD) administered once daily in healthy volunteers[J]. Am J Ther,1999,6:211.
[8]顾健,于芝颖,郑红毅,等.国产盐酸地尔硫缓释胶囊的药代动力学研究[J].中国临床药理学杂志,2002,18:122.
[9]Pichard J,Gillet G,Fabre I,et al. Identification of the rabbit and human cytochromes P-450ⅢA as the major enzymes involved in the N-demethylation of diltiazem[J]. Drug Metab Dispos,1990,18:711.
[10]Molden E,Asberg A,Christensen H.Desacetyl-diltiazem displays several fold higher affinity to CYP2D6 compared with CYP3A4[J]. Drug Metab Dispos,2002,30:1.
[11]Sutton D,Butler AM,Nadin L,et al. Role of CYP3A4 in human hepatic diliazem N-demethylation:inhibition of CYP3A4 activity by oxidized ditiamzem metabolites[J]. J Pharmacol Exp Ther,1997,282:294.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
